Status:
COMPLETED
CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing
Lead Sponsor:
National Taiwan University Hospital
Conditions:
GERD
Eligibility:
All Genders
20-80 years
Phase:
PHASE4
Brief Summary
Background/Aim: To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P (CYP) 2C19 pol...
Detailed Description
INTRODUCTION A broad spectrum of symptoms are commonly associated with gastroesophageal reflux disease (GERD), which has an incidence of roughly 20% in the general population.\[1\] Despite recent, sub...
Eligibility Criteria
Inclusion
- A consecutive series of patients with symptoms suggestive of GERD were enrolled from the Gastroenterology outpatient clinic in our institution. The typical GERD symptom was defined as heartburn and/or acid regurgitation of at least three episodes per week for a minimum of three months.
Exclusion
- Patients who received concurrent PPI treatment, had a medical contraindication to rabeprazole therapy, reported a history of peptic ulcer disease or gastrointestinal surgery, peptic ulcer disease or malignancy proven by endoscopy, the presence of alarm features (e.g., dysphagia, weight loss, bleeding, abdominal mass, and/or anemia), or who were unwilling or unable to provide informed consent were excluded from the study.
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00354757
Start Date
June 1 2005
End Date
December 1 2008
Last Update
December 3 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan Univeristy Hospital
Taipei, Taipei, Taiwan, 100